Skip to main content

Advertisement

SpringerLink
Log in

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background Blocking of EGFR signaling by the tyrosine kinase inhibitor AEE788 was well tolerated and did not inhibit liver regeneration after standard 70% partial hepatectomy (PH) in a rat model, as demonstrated previously. However, serum levels of AEE788 at POW1 were 3-fold higher than in the non-resected control group. Therefore, we expanded theses studies to a model of extended 90%PH to investigate the role of liver size for the metabolism of AEE788 and its potential influence on side effects, liver regeneration and liver remodeling. Method Rats treated with 50 mg/kg AEE788 or solvent every other day orally were subjected to 90%PH. Animals were sacrificed at 1, 2, 7 and 28 days after PH. We measured plasma and liver levels of AEE788 and assessed anti-proliferative side effects, liver regeneration, and liver architecture. Result Liver regeneration and liver architecture were not impaired by AEE788 treatment after 90%PH. 90%PH caused a clinically relevant drug accumulation within 1 week of treatment (AEE788 serum and tissue levels: 90%PH*>70%PH*>normal control, *p < 0.05), suggesting a liver-size-dependent metabolism of the drug. Drug accumulation after 90%PH was associated with severe side effects (delayed body weight recovery, diarrhea, impaired hair growth) within 1 week of treatment. Conclusion Treatment with AEE788 could be a potential strategy for adjuvant treatment after oncological liver resection, as liver regeneration was not impaired. Our results suggest a liver-size-dependent metabolism of AEE788 leading to drug accumulation and subsequently to severe side effects. It calls for therapeutic drug monitoring in the early postoperative phase after extended resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  2. Wilson RH (2006) Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist 11:1018–1024

    Article  PubMed  CAS  Google Scholar 

  3. Overman MJ, Hoff PM (2007) EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum 50:1259–1270

    Article  PubMed  Google Scholar 

  4. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH (2007) Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14:786–794

    Article  PubMed  Google Scholar 

  5. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722, discussion

    Article  PubMed  Google Scholar 

  6. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM (2007) Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 246:183–191

    Article  PubMed  Google Scholar 

  7. Van Buren G, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ, Ellis LM (2008) Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 26:1836–1842

    Article  PubMed  Google Scholar 

  8. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64:4931–4941

    Article  PubMed  CAS  Google Scholar 

  9. Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim JS, Langley RR, Fan D, Wang X, Do KA, Kim SJ, Fidler IJ (2008) Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 25(4):477–489

    Article  PubMed  CAS  Google Scholar 

  10. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J, Kim SJ, Abbruzzese JL, Hamilton SR, Fidler IJ (2005) Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 65:3716–3725

    Article  PubMed  CAS  Google Scholar 

  11. Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJ (2006) Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 8:747–757

    Article  PubMed  CAS  Google Scholar 

  12. Deng M, Huang H, Dirsch O, Dahmen U (2009) Effect and risk of AEE788, a dual tyrosine kinase inhibitor, on regeneration in a rat liver resection model. accepted by European Surgical Research

  13. Madrahimov N, Dirsch O, Broelsch C, Dahmen U (2006) Marginal hepatectomy in the rat: from anatomy to surgery. Ann Surg 244:89–98

    Article  PubMed  Google Scholar 

  14. Meco D, Riccardi A, Servidei T, Brueggen J, Gessi M, Riccardi R, Dominici C (2005) Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett 228:211–219

    Article  PubMed  CAS  Google Scholar 

  15. Deng M, Kleinert R, Huang H, He Q, Madrahimova F, Dirsch O, Dahmen U (2009) Statistical and economical efficiency in assessment of liver regeneration using defined sample size and selection in combination with a fully automated image analysis system. J Histochem Cytochem 57(11):1075–1085

    Article  PubMed  CAS  Google Scholar 

  16. Xing W, Deng M, Zhang J, Huang H, Dirsch O, Dahmen U (2009) Quantitative evaluation and selection of reference genes in a rat model of extended liver resection. J Biomol Tech 20:109–115

    PubMed  Google Scholar 

  17. Gasparini G, Harris AL (1995) Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13:765–782

    PubMed  CAS  Google Scholar 

  18. Washington K, Lane KL, Meyers WC (1993) Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol 17:1151–1158

    Article  PubMed  CAS  Google Scholar 

  19. Skarpen E, Oksvold MP, Grosvik H, Widnes C, Huitfeldt HS (2005) Altered regulation of EGF receptor signaling following a partial hepatectomy. J Cell Physiol 202:707–716

    Article  PubMed  CAS  Google Scholar 

  20. Fabrikant JI (1968) The kinetics of cellular proliferation in regenerating liver. J Cell Biol 36:551–565

    Article  PubMed  CAS  Google Scholar 

  21. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK (2007) Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67:281–288

    Article  PubMed  CAS  Google Scholar 

  22. Busby JE, Kim SJ, Yazici S, Nakamura T, Kim JS, He J, Maya M, Wang X, Do KA, Fan D, Fidler IJ (2006) Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells. Prostate 66:1788–1798

    Article  PubMed  CAS  Google Scholar 

  23. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, Bekele BN, Fidler IJ, Myers JN (2004) Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64:7977–7984

    Article  PubMed  CAS  Google Scholar 

  24. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, Mossner J, Caca K (2006) Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17:783–795

    Article  PubMed  CAS  Google Scholar 

  25. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R (2006) Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12:4441s–4445s

    Article  PubMed  CAS  Google Scholar 

  26. Okamoto K, Neureiter D, Alinger B, Meissnitzer M, Sass G, Schmitz V, Di Fazio P, Wissniowski T, Gahr S, Hohenstein B, Kaufmann B, Schlosser A, Haus U, Hahn EG, Herold C, Ocker M (2008) The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol 33:733–742

    PubMed  CAS  Google Scholar 

  27. Takada T, Weiss HM, Kretz O, Gross G, Sugiyama Y (2004) Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154. Drug Metab Dispos 32:1272–1278

    Article  PubMed  CAS  Google Scholar 

  28. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malago M, Jalan R, Saner FH (2008) Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 28:767–780

    Article  PubMed  Google Scholar 

  29. Pennell NA, Lynch TJ Jr (2009) Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14:399–411

    Article  PubMed  CAS  Google Scholar 

  30. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2007) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99(1):159–165

    PubMed  Google Scholar 

  31. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R, Jankowski J (2007) A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13:5869–5875

    Article  PubMed  CAS  Google Scholar 

  32. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC (2006) Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108:3674–3681

    Article  PubMed  CAS  Google Scholar 

  33. Lacouture ME (2007) Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs 30:S17–S26

    Article  PubMed  Google Scholar 

  34. Alison MR, Sarraf CE (1994) The role of growth factors in gastrointestinal cell proliferation. Cell Biol Int 18:1–10

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Heinrich Hertz-Stiftung.

We thank Ines Krimphoff for excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Hufelandstrasse 55, 45122, Essen, Germany

    Meihong Deng, Hai Huang, Hao Jin & Uta Dahmen

  2. Division of Pathology, Deutsches Herzzentrum, Berlin, Germany

    Olaf Dirsch

Authors
  1. Meihong Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olaf Dirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uta Dahmen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uta Dahmen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deng, M., Huang, H., Jin, H. et al. The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats. Invest New Drugs 29, 593–606 (2011). https://doi.org/10.1007/s10637-010-9394-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-010-9394-6

Keywords

Search

Navigation